It may be that they recognized VRTX's first in class technologies in target/drug molecule imaging, computational drug design, and maturity in management and as a pharmaceutical company, etc. etc... Such intellectual properties will generate future revenues.
Watch the price movement of ALNY. It has more than doubled since mid-July. The most advanced drug candidate it has is in early Phase 1, and yet, it is in Russell 2000.